Inovio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Inovio Pharmaceuticals has a total shareholder equity of $73.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $107.1M and $33.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$84.80m |
| Equity | US$73.54m |
| Total liabilities | US$33.52m |
| Total assets | US$107.06m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GBM's short term assets ($91.3M) exceed its short term liabilities ($23.5M).
Long Term Liabilities: GBM's short term assets ($91.3M) exceed its long term liabilities ($10.0M).
Debt to Equity History and Analysis
Debt Level: GBM is debt free.
Reducing Debt: GBM has no debt compared to 5 years ago when its debt to equity ratio was 194%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GBM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.5% each year